{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.59","value":"-2.1"},{"groupId":"OG001","spread":"1.95","value":"-3.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"149"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.69","value":"-4.5"},{"groupId":"OG001","spread":"2.54","value":"-6.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.76","value":"-4.2"},{"groupId":"OG001","spread":"3.03","value":"-2.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"182"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Cycle 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"330"},{"groupId":"OG001","value":"149"}],"units":"Participants"}],"description":"EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and global health status/QOL scale. EORTC QLQ-C30 contains 28 questions (4-point scale where 1=Not at all \\[best\\] to 4=Very Much \\[worst\\]) and 2 questions (7-point scale where 1=Very poor \\[worst\\] to 7= Excellent \\[best\\]). Raw scores are standardized and converted into scale scores ranging from 0 to 100. For global health status/QOL scale, higher scores represent better QOL. A negative change from baseline value indicates patient condition worsened. Change from baseline in the EORTC QLQ-C30 Global Health Status/Quality of Life Scale scores was performed by visit (i.e., cycle), using a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach.","dispersionType":"Standard Error","groups":[{"description":"Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG000","title":"Fruquintinib + BSC Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG001","title":"Placebo + BSC Group"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"ITT population included all randomized participants. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"Number analyzed\" signifies those participants who were evaluable at the specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 2, 3 and 4 (Each cycle=28 days)","title":"Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life (QOL) Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status/Quality of Life Scale Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}